[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112012017277A2 - Compostos e métodos - Google Patents

Compostos e métodos

Info

Publication number
BR112012017277A2
BR112012017277A2 BR112012017277A BR112012017277A BR112012017277A2 BR 112012017277 A2 BR112012017277 A2 BR 112012017277A2 BR 112012017277 A BR112012017277 A BR 112012017277A BR 112012017277 A BR112012017277 A BR 112012017277A BR 112012017277 A2 BR112012017277 A2 BR 112012017277A2
Authority
BR
Brazil
Prior art keywords
compounds
methods
formula
disclosed
making
Prior art date
Application number
BR112012017277A
Other languages
English (en)
Inventor
Zhao Yongdong
S Kallander Lara
Griffin Lawhorn Brian
Philp Joanne
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112012017277A2 publication Critical patent/BR112012017277A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

COMPOSTOS E MÉTODOS. São revelados compostos tendo a fórmula: onde R1, R2, R4, R5 e R6 são como definido aqui, e os métodos de fazer e usar o mesmo.
BR112012017277A 2010-01-13 2011-01-11 Compostos e métodos BR112012017277A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29463710P 2010-01-13 2010-01-13
PCT/US2011/020798 WO2011088027A1 (en) 2010-01-13 2011-01-11 Compounds and methods

Publications (1)

Publication Number Publication Date
BR112012017277A2 true BR112012017277A2 (pt) 2017-10-03

Family

ID=44304601

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017277A BR112012017277A2 (pt) 2010-01-13 2011-01-11 Compostos e métodos

Country Status (13)

Country Link
US (1) US20120329784A1 (pt)
EP (1) EP2523559A4 (pt)
JP (1) JP2013517273A (pt)
KR (1) KR20120114355A (pt)
CN (1) CN102791131A (pt)
AU (1) AU2011205485B2 (pt)
BR (1) BR112012017277A2 (pt)
CA (1) CA2786999A1 (pt)
EA (1) EA201290642A1 (pt)
IL (1) IL220812A0 (pt)
MX (1) MX2012008141A (pt)
SG (1) SG182351A1 (pt)
WO (1) WO2011088027A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358172B (es) * 2012-05-03 2018-08-08 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
EP2967049B1 (en) * 2013-03-15 2020-09-02 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN104844526B (zh) * 2015-04-16 2018-08-31 温州医科大学 一种4,6-嘧啶二胺类化合物及其制备方法和应用
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
JP6165373B1 (ja) * 2017-02-24 2017-07-19 タマ化学工業株式会社 ピリジン−３−スルホニルクロリドの製造方法
US12110286B2 (en) 2017-05-26 2024-10-08 Cancer Research Technology Limited Benzimidazolone derived inhibitors of BCL6
CN108864052A (zh) * 2018-06-07 2018-11-23 福建医科大学 一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用
EP4206196A1 (en) * 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
WO2023196714A2 (en) * 2022-02-23 2023-10-12 President And Fellows Of Harvard College Inhibitors of ddr1 and ddr2 for the treatment of arthritis
US11891362B1 (en) * 2023-04-14 2024-02-06 King Faisal University N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1678147B1 (en) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
BRPI0506839A (pt) * 2004-01-16 2007-06-12 Novartis Ag composições e métodos para induzir a cardiomiogênese
EP1709007A1 (en) * 2004-01-22 2006-10-11 Altana Pharma AG N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
UA109411C2 (uk) * 2005-11-01 2015-08-25 N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки
PT1951684T (pt) * 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
US20070293494A1 (en) * 2006-06-15 2007-12-20 Djung Jane F 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
CN101589036A (zh) * 2006-12-19 2009-11-25 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶
US7947698B2 (en) * 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
TWI475996B (zh) * 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途

Also Published As

Publication number Publication date
KR20120114355A (ko) 2012-10-16
EP2523559A1 (en) 2012-11-21
AU2011205485B2 (en) 2014-09-25
SG182351A1 (en) 2012-08-30
US20120329784A1 (en) 2012-12-27
EP2523559A4 (en) 2013-11-06
EA201290642A1 (ru) 2013-05-30
AU2011205485A1 (en) 2012-08-02
CN102791131A (zh) 2012-11-21
IL220812A0 (en) 2012-08-30
WO2011088027A8 (en) 2012-08-30
JP2013517273A (ja) 2013-05-16
MX2012008141A (es) 2012-08-03
CA2786999A1 (en) 2011-07-21
WO2011088027A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
BR112012017277A2 (pt) Compostos e métodos
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
UA107791C2 (en) Pesticidal compositions
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
IN2015DN00960A (pt)
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
EA201792039A1 (ru) Гетероциклические амины в качестве ингибиторов киназы
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UA113643C2 (xx) N-цикліламіди як нематоциди
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
ECSP11011245A (es) Novedosos herbicidas
UY34442A (es) 2-tiopirimidinonas.
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
EA201591349A1 (ru) Способ получения вортиоксетина
UY33976A (es) Derivados de pirazolo-pirimidina.
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201170585A1 (ru) Производные изохинолинона в качестве антагонистов nk3
EA201000069A1 (ru) Новые гербициды
CL2016001488A1 (es) Quinazolin-thf-aminas como inhibidores de pde1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]